New epigenetic drug against Mantle Cell Lymphoma
Jun 13, 2018, Drug Target Review (UK)
A new study presents an epigenetic drug capable of slowing down cell growth in Mantle Cell Lymphoma (MCL)…
https://www.drugtargetreview.com/news/32438/epigenetic-drug-mantle-cell-lymphoma/
QUIMATRYX DEVELOPS AN EFFECTIVE EPIGENETIC DRUG AGAINST MANTLE CELL LYMPHOMA
QUIMATRYX has developed an epigenetic drug that has shown great efficacy in animal models against Mantle Cell Lymphoma.
https://lymphomanewstoday.com/2018/06/21/qtx125-slows-mantle-cell-lymphoma-progression-mouse-study/
Researchers Develop New Epigenetic Drug Against Mantle Cell Lymphoma
Jun 12, 2018, Pharmaceutical Processing
https://www.rdmag.com/news/2018/06/researchers-develop-new-epigenetic-drug-against-mantle-cell-lymphoma
Investor search in Quimatryx
Quimatryx has hired NORGESTION to search for one or more partners to rise €3 Million in two planned financial rounds between 2018 and 2019. This amount will be used to develop Quimatryx compound QTX125 (selective inhibitor against HDAC6) to clinical phase I for mantle cell lymphoma.